Recent advances in anti-tuberculous drug development and novel drug targets

Expert Review of Respiratory Medicine

Volumn 2, Issue 4, 2008, Pages 455-471

  Tomioka, Haruaki ^a   Tatano, Yutaka ^a   Yasumoto, Ko ^a   Shimizu, Toshiaki ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Anti tuberculous drug; Chemotherapy; Drug target; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIMYCOBACTERIAL AGENT; ARABINOGALACTAN; AX 14585; AX 20017; AX 33510; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ETHAMBUTOL; ETHYLENEDIAMINE; ISONIAZID; LINEZOLID; METHYLTRANSFERASE; METRONIDAZOLE; MOXIFLOXACIN; MYCOLIC ACID; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NITROIMIDAZOLE DERIVATIVE; NITROIMIDAZOOXAZOLE DERIVATIVE; OPC 67683; OXAZOLIDINONE DERIVATIVE; PA 1343; PEPTIDOGLYCAN; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HOST CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIGNAL TRANSDUCTION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 55149115626     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.4.455     Document Type: Review

References (146)

1. Frieden TR, Sterling TR, Munsiff SS, Wart CJ, Dye C. Tuberculosis. Lancet 362, 887-899 (2003).
2. Duncan K. Identification and validation of novel drug targets in tuberculosis. Curr. Pharm. Des. 10, 3185-3194 (2004).
3. Kantardjieff K, Rupp B. Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr. Pharm. Des. 10, 3195-3211 (2004).
4. Ballell L, Field RA, Duncan K, Young RJ. New small-molecule synthetic antimycobacterials. Antimicrob. Agents Chemother. 49, 2153-2163 (2005).
5. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. 12, 4047-4070 (2006).
6. Janin YL. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479-2513 (2007).
7. Tomioka H. Development of new antituberculous agents based on new drug targets and structure-activity relationship. Expert Opin. Drug Discov. 3, 1-29 (2008).
8. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
9. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184, 5479-5490 (2002).
10. Barker JJ. Antibacterial drug discovery and srtucture-based design. Drug Discov. Today 11, 391-404 (2006).
11. Glickman MS, Jacobs WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 104, 477-485 (2001).
12. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16, 463-496 (2003).
13. Terwilliger TC, Park MS, Waldo GS et al. The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology. Tuberculosis (Edinb.) 83, 223-249 (2003).
14. Smith CV, Sharma V, Sacchettini JC. TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinb.) 84, 45-55 (2004).
15. Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000).
16. Bhatt A, Fujiwara N, Bhart K et al. Deletion of kas B in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc. Natl Acad. Sci. USA 104, 5157-5162 (2007).
17. Musayev F, Sachdeva S, Scarsdale JN, Reynolds KA, Wright HT. Crystal structure of a substrate complex of Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A. J. Mol. Biol. 346, 1313-1321 (2005).
18. Portevin D, de Sousa-D'Auria C, Montrozier H et al. The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J. Biol. Chem. 280, 8862-8874 (2005).
19. Portevin D, De Sousa-D'Auria C, Houssin C et al. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc. Natl Acad. Sci. USA 101, 314-319 (2004).
20. Minnikin DE. Lipids: complex lipids. In: The Biology of Mycobacteria. Ratledge C, Stanford J (Eds). Academic Press, CA, USA 95-184 (1982).
21. Yuan Y, Lee RE, Besra GS, Belisle JT, Barry CE 3rd. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 92 6630-6634 (1995).
22. George KM, Yuan Y, Sherman DR, Barry CE 3rd. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Identification and functional analysis of CMAS-2. J. Biol. Chem. 270, 27292-27298 (1995).
23. Banerjee A, Dubnau E, Quemard A et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994).
24. de Boer GJ, Pielage GJ, Nijkamp HJ et al. Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine. Mol. Microbiol. 31, 443-450 (1999).
25. Slayden RA, Lee RE, Barry CE 3rd. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38, 514-525 (2000).
26. Boyne ME, Sullivan TJ, amEnde CW et al. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob. Agents Chemother. 51, 3562-3567 (2007).
27. Sibley LD, Hunter SW, Brennan PJ, Krahenbuhl JL. Mycobacterial lipoarabinomannan inhibits γ interferon-mediated activation of macrophages. Infect. Immun. 56, 1232-1236 (1988).
28. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59, 1755-1761 (1991).
29. Cox JS, Chen B, McNeil M, Jacobs WR. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79-83 (1999).
30. Gurcha SS, Baulard AR, Kremer L et al. Ppm1, a novel polyprenol monophosphomannose synthase from Mycobacterium tuberculosis. Biochem. J. 365, 441-450 (2002).
31. Schaeffer ML, Khoo KH, Besra GS et al. The pimB gene of Mycobacterium tuberculosis encodes a mannosyltransferase involved in lipoarabinomannan biosynthesis. J. Biol. Chem. 274, 31625-31631 (1999).
32. Alexander DC, Jones JR, Tan T, Chen JM, Liu J. PimF, a mannosyltransferase of mycobacteria, is involved in the biosynthesis of phosphatidylinositol mannosides and lipoarabinomannan. J. Biol. Chem. 279, 18824-18833 (2004).
33. Buglino J, Onwueme KC, Ferreras JA, Quadri LE, Lima CD. Crystal structure of PapA5, a phthiocerol dimycocerosyl transferase from Mycobacterium tuberculosis. J. Biol. Chem. 279, 30634-30642 (2004).
34. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 83, 91-97 (2003).
35. Ma Y, Stern RJ, Scherman MS et al. Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob. Agents Chemother. 45, 1407-1416 (2001).
36. Li W, Xin Y, McNeil MR, Ma Y. rmlB and rmlC genes are essential for growth of mycobacteria. Biochem. Biophys. Res. Commun. 342, 170-178 (2006).
37. Kantardjieff KA, Kim CY, Naranjo C et al. Mycobacterium tuberculosis RmlC epimerase (Rv3465): a promising drug-target structure in the rhamnose pathway. Acta. Crystallogr. D Biol. Crystallogr. 60, 895-902 (2004).
38. Mikusov K, Mikus M, Besra GS, Hancock I, Brennan PJ. Biosynthesis of the linkage region of the mycobacterial cell wall. J. Biol. Chem. 271, 7820-7828 (1996).
39. Sharma V, Hudspeth ME, Meganathan R. Menaquinone (vitamin K2) biosynthesis: localization and characterization of the menE gene from Escherichia coli. Gene 168, 43-48 (1996).
40. Eoh H, Brown AC, Buetow L et al. Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development. J. Bacteriol. 189, 8922-8927 (2007).
41. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77-84 (2003).
42. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect. Immun. 37, 1042-1049 (1982).
43. Graham JE, Clark-Curtiss JE. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocyrosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc. Natl Acad. Sci. USA 96, 11554-11559 (1999).
44. Höner Zu Bentrup K, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol. 181, 7161-7167 (1999).
45. Gould TA, van de Langemheen H, Muñoz-Elías EJ, McKinney JD, Sacchettini JC. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis. Mol. Microbiol. 61, 940-947 (2006).
46. McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
47. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, Her zu Bentrup K. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J. Biol. Chem. 278, 1735-1743 (2003).
48. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antinticrob. Agents Chemother. 51, 1380-1385 (2007).
49. Murphy DJ, Brown JR. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect. Dis. 7, 84-99 (2007).
50. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731 (2002).
51. Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad Sci. USA 100, 12989-12994 (2003).
52. Talaat AM, Lyons R, Howard ST, Johnston SA. The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc. Natl Acad. Sci. USA 101, 4602-4607 (2004).
53. Voskuil MI, Visconti KC, Schoolnik GK, Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb.) 84, 218-227 (2004).
54. Hampshire T, Soneji S, Bacon J et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb.) 84, 228-238 (2004).
55. Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl Acad. Sci. USA 102, 8327-8332 (2005).
56. Koul A, Herget T, Klebl B, Ullrich A. Interplay between mycobacteria and host signalling pathways. Nat. Rev. Microbiol. 2, 189-202 (2004).
57. Tse HM, Josephy SI, Chan ED, Fouts D, Cooper AM. Activation of the mitogen-activated protein kinase signaling pathway is instrumental in determining the ability of Mycobacterium avium to grow in murine macrophages. J. Immunol. 168, 825-833 (2002).
58. Walburger A, Koul A, Ferrari G et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304, 1800-1804 (2004).
59. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77-84 (2003).
60. Székely R, Wáczek F, Szabadkai I et al. A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol. Lett. 116, 225-231 (2008).
61. Kuijl C, Savage ND, Marsman M et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT 1. Nature 450, 725-730 (2007).
62. Barry CE 3rd, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10, 3239-3262 (2004).
63. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054-2058 (1994).
64. Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L. Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1537-1540 (2007).
65. Stover CK, Warrener P, Van Devanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000).
66. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431-436 (2006).
67. Nuermberger E, Rosenthal I, Tyagi S et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50, 2621-2625 (2006).
68. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PloS Med. 3, 2131-2144 (2006).
69. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
70. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323-324 (2007).
71. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853-2856 (2006).
72. Ibrahim M, Andries K, Lounis N et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51, 1011-1015 (2007).
73. McNeeley DF. Update on the clinical development program of TMC207 (R207910), Tibotec, Inc., Yardley, PA, USA. Presented at: Open Forum. London, UK, 12-13 December, 2006.
74. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43, 1189-1191 (1999).
75. Sood R, Rao M, Singhal S, Rattan A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int. J. Antimicrob. Agents 25, 464-468 (2005).
76. Sood R, Bhadauriya T, Rao M et al. Antimycobacterial activities of oxazolidinones: a review. Infect. Disord. Drug Targets 6, 343-354 (2006).
77. Vera-Cabrera L, Gonzalez E, Rendon A et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother. 50, 3170-3172 (2006).
78. Alcala L, Ruiz-Serrano MJ, Perez-Fernandez G et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 47, 416-417 (2003).
79. Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Int. J. Antimicrob. Agents 29, 322-325 (2007).
80. Rao M, Sood R, Malhotra S, Fatma T, Upadhyay DJ, Rattan A. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex. J. Chemother. 18, 144-150 (2006).
81. Fortún J, Martín-Dáivila P, Navas E et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180-185 (2005).
82. Vera-Cabrera L, Castro-Garza J, Rendon A et al. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob. Agents Chemother. 49, 4351-4353 (2005).
83. Malhotra S, Gautam R, Bhadauriya T, Rudra S, Das B. In vivo activity of RBx 8700 against Mycobacterium tuberculosis. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September, 2003.
84. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 58, 332-337 (2006).
85. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother. 51, 1563-1565 (2007).
86. Deidda D, Lampis G, Fioravanti R et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. 42, 3035-3037 (1998).
87. Arora S, Sinha N, Sinha RK et al. Synthesis and in vitro anti-mycobacterial activity of a novel anti-TB composition of LL3858. Presented at: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November, 2004.
88. Sinha RK, Arora S, Sinha N, Modak VM. In vivo activity of LL3858 against Mycobacterium tuberculosis. Presented at: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November, 2004.
89. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother. 28, 716-721 (1985).
90. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3, 432-442 (2003).
91. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 4, 2066-2069 (1998).
92. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother. 43, 3001-3004 (1999).
93. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46, 1022-1025 (2002).
94. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48, 780-782 (2004).
95. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196(Suppl. 1), S28-S34 (2007).
96. Smart T. Experts debate how to develop drugs specifically for MDR TB. Aidsmap News. London, UK (2007).
97. McNeeley D, Cavaleri M. TMC 207 oral presentation. TBTC 17th Semi-Annual Group Meeting, San Diego, CA, USA, 20 May, 2005.
98. Ginsberg AM. Development of new drugs for TB. Presented at: Infectious Diseases Society of America Annual Meeting. San Diego, CA, USA, 4-7 October, 2007.
99. de Boer GJ, Pielage GJ, Nijkamp HJ et al. Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine. Mol. Microbiol. 31, 443-450 (1999).
100. Cohen-Gonsaud M, Ducasse S, Hoh F, Zerbib D, Labesse G, Quemard A. Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis. J. Mol. Biol. 320, 249-261 (2002).
101. Schaeffer ML, Agnihotri G, Volker C, Kallender H, Brennan PJ, Lonsdale JT. Purification and biochemical characterization of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthases KasA and KasB. J. Biol. Chem. 276, 47029-47037 (2001).
102. Glickman MS, Cahill SM, Jacobs WR Jr. The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid transcyclopropane synthetase. J. Biol. Chem. 276, 2228-2233 (2001).
103. Glickman MS. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal cyclopropane synthase of the α-mycolic acid. J. Biol. Chem. 278, 7844-7849 (2003).
104. Boissier F, Bardou F, Guillet V et al. Further insight into S-adenosylmethionine-dependent methyltransferases: structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis. J. Biol. Chem. 281, 4434-4445 (2006).
105. Lin TW, Melgar MM, Kurth D et al. Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 3072-3077 (2006).
106. Buchmeier N, Fahey RC. The mshA gene encoding the glycosyltransferase of mycothiol biosynthesis is essential in Mycobacterium tuberculosis Erdman. FEMS Microbiol. Lett. 264, 74-79 (2006).
107. Newton GL, Ko M, Ta P, Av-Gay Y, Fahey RC. Purification and characterization of Mycobacterium tuberculosis 1D-myo-inosityl-2-acetamido-2-deoxy-α-D-glucopyranoside deacetylase, MshB, a mycothiol biosynthetic enzyme. Protein Expr. Purif. 47, 542-550 (2006).
108. Newton GL, Ta P, Sareen D, Farley RC. A coupled spectrophotometric assay for L-cysteine: 1-D-myo-inosityl 2-amino-2-deoxy-α-D-glucopyranoside ligase and its application for inhibitor screening. Anal. Biochem. 353, 167-173 (2006).
109. Vetting MW, Roderick SL, Yu M, Blanchard JS. Crystal structure of mycothiol synthase (Rv0819) from Mycobacterium tuberculosis shows structural homology to the GNAT family of N-acetyltransferases. Protein Sci. 12, 1954-1959 (2003).
110. Guerin ME, Buschiazzo A, Korduláková J, Jackson M, Alzari PM. Crystallization and preliminary crystallographic analysis of PimA, an essential mannosyhransferase from Mycobacterium smegmatis. Acta. Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 61, 518-520 (2005).
111. Dinev Z, Gannon CT, Egan C, Watt JA, McConville MJ, Williams SJ. Galactose-derived phosphonate analogues as potential inhibitors of phosphatidylinositol biosynthesis in mycobacteria. Org. Biomol. Chem. 5, 952-959 (2007).
112. Jain M, Cox JS. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PloS Pathog. 1, e2 (2005).
113. Huang Q, Kirikae F, Kirikae T et al. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J. Med. Chem. 49, 463-466 (2006).
114. Kurosu M, Narayanasamy P, Biswas K, Dhiman R, Crick DC. Discovery of 1,4-dihydroxy-2-naphthoate prenyltransferase inhibitors: new drug leads for multidrug-resistant Gram-positive pathogens. J. Med. Chem. 50, 3973-3975 (2007).
115. Johnston JM, Arcus VL, Baker EN. Structure of naphthoate synthase (MenB) from Mycobacterium tuberculosis in both native and product-bound forms. Acta. Crystallogr. D Biol. Crystallogr. 61, 1199-1206 (2005).
116. Weinstein EA, Yano T, Li LS et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl Acad. Sci. USA 102, 4548-4553 (2005).
117. Senaratne RH, De Silva AD, Williams SJ et al. 5′ -Adenosinephosphosulphate reductase (CysH) protects Mycobacterium tuberculosis against free radicals during chronic infection phase in mice. Mol. Microbiol. 59, 1744-1753 (2006).
118. Nopponpunth V, Sirawaraporn W, Greene PJ, Santi DV. Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J. Bacteriol. 181, 6814-6821 (1999).
119. White EL, Ross LJ, Cunningham A, Escuyer V. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase. FEMS Microbiol. Lett. 232, 101-105 (2004).
120. Sambandamurthy VK, Wang X, Chen B et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. 8, 1171-1174 (2002).
121. Chopra S, Pai H, Ranganathan A. Expression, purification, and biochemical characterization of Mycobacterium tuberculosis aspartate decarboxylase, PanD. Protein Expr. Purif. 25, 533-540 (2002).
122. Höner Zu Bentrup K, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol. 181, 7161-7167 (1999).
123. Sharma V, Sharma S, Hoener zu Bentrup K et al. Structure of isocitrate lyase, a persistence factor 3 of Mycobacterium tuberculosis. Nat. Struct. Biol. 7, 663-668 (2000).
124. Muñoz-Elías EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11, 638-644 (2005).
125. Wang Y, Long MC, Ranganathan S, Escuyer V, Parker WB, Li R. Overexpression, purification and crystallographic analysis of a unique adenosine kinase from Mycobacterium tuberculosis. Acta. Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 61, 553-557 (2005).
126. Long MC, Parker WB. Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. I. Modifications to the adenine moiety. Biochem. Pharmacol. 71, 1671-1682 (2006).
127. Long MC, Allan PW, Luo MZ, Liu MC, Sartorelli AC, Parker WB. Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth. J. Antimicrob. Chemother. 59, 118-121 (2007).
128. Munier-Lehmann H, Chaffotte A, Pochet S, Labesse G. Thymidylate kinase of Mycobacterium tuberculosis: a chimera sharing properties common to eukaryotic and bacterial enzymes. Protein Sci. 10, 1195-1205 (2001).
129. Vanheusden V, Munier-Lehmann H, Froeyen M et al. Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase. J. Med. Chem. 47, 6187-6194 (2004).
130. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 51, 4202-4204 (2007).
131. Edwards KM, Cynamon MH, Voladri RK et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 164, 2213-2219 (2001).
132. Shi S, Ehrt S. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect. Immun. 74, 56-63 (2006).
133. Rajashankar KR, Bryk R, Kniewel R, Buglino JA, Nathan CF, Lima CD. Crystal structure and functional analysis of lipoamide dehydrogenase from Mycobacterium tuberculosis. J. Biol. Chem. 280, 33977-33983 (2005).
134. Ranjan S, Yellaboina S, Ranjan A. IdeR in mycobacteria: from target recognition to physiological function. Crit. Rev. Microbiol. 32, 69-75 (2006).
135. Wisedchaisri G, Chou CJ, Wu M et al. Crystal structures, metal activation, and DNA-binding properties of two-domain IdeR from Mycobacterium tuberculosis. Biochemistry 46, 436-447 (2007).
136. Saini DK, Malhotra V, Tyagi JS. Cross talk between DevS sensor kinase homologue, Rv2027c, and DevR response regulator of Mycobacterium tuberculosis. FEBS Lett. 565, 75-78 (2004).
137. Wisedchaisri G, Wu M, Rice AE, Roberts DM, Sherman DR, Hol WG. Structures of Mycobacterium tuberculosis DosR and DosR-DNA complex involved in gene activation during adaptation to hypoxic latency. J. Mol. Biol. 354, 630-641 (2005).
138. DaM JL, Arora K, Boshoff HI et al. The relA homolog of Mycobacterium smegmatis affects cell appearance, viability, and gene expression. J. Bacteriol. 187, 2439-2447 (2005).
139. Join V, Saleem-Batcha R, China A, Chatterji D. Molecular dissection of the mycobacterial stringent response protein Rel. Protein Sci. 15, 1449-1464 (2006).
140. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49, 2289-2293 (2005).
141. Lenaerts AJ, Gruppo V, Marietta KS et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49, 2294-2301 (2005).
142. Reddy VM, Nadadhur G, Daneluzzi D, O'Sullivan JF, Gangadharam PRJ. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40, 633-636 (1996).
143. Reddy VM, O'Sullivan JF, Gangadharam PRJ. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43, 615-623 (1999).
144. Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J. Antimicrob. Chemother. 47, 199-202 (2001).
145. van Rensberg CE, Joone GK, Sirgel FA, Matlola NM, O'Sullivan JF. In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis. Chemotherapy 46, 43-48 (2000).
146. Maccari R, Ottaná R, Monforte F, Vigorita MG. In vitro antimycobacterial activities of 2′-monosubstituted isonicotinohydrazides and their cyanoborane adducts. Antimicrob. Agents Chemother. 46, 294-299 (2002).